ТИРОНЕТ – все о щитовидной железе Для специалистов Журнал Тиронет Архив журнала 2003 год № 3

Этиология, диагностика и лечение болезни Грейвса

Энтони Уитман, Шеффилд (Великобритания)/Anthony P. Weetman (University of Sheffield, UK)
Thyroid international — 2 — 2003
Русский перевод к.м.н. Фадеева В. В. (примечания и комментарии переводчика отмечены *)

ЛИТЕРАТУРА

  1. Davies T.F. Newer Aspects of Graves' Disease. // Bailliere's Clin Endocrinol Metab — 1997 — Vol. 11. — P. 431 — 601.
  2. Rapoport B., McLachlan S.M. Graves' Disease: Pathogenesis and Treatment, Kluwer Academic Publishers. — Boston, USA, 2000.
  3. Prummel M.F. Recent Developments in Graves' Ophthalmopathy. — Kluwer Academic Publishers, Boston, USA, 2000.
  4. Bartalena L., Pinchera A., Marcocci C. Management of Graves' ophthalmopathy: Reality and perspectives. // Endocrine Rev — 2000 — Vol. 21. — P. 168 — 199.
  5. Brix T.H., Kyvik K.O., Christensen K., Hegedus L. Evidence for a major role of heredity in Graves' disease: A population-based study of two Danish twin cohorts. // J Clin Endocrinol Metab — 2001 — Vol. 86. — P. 930 — 934.
  6. Heward J.M., Allahabadia A., Daykin J., et al. Linkage disequilibrium between the human leukocyte antigen class II region of the major histocompatibility complex and Graves' disease: Replication using a population case control and family-based study. // J Clin Endocrinol Metab — 1998 — Vol. 83. — P. 3394 — 3397.
  7. Kotsa K., Watson P.F., Weetman A.P. A CTLA-4 gene polymorphism is associated with both Graves' disease and Hashimoto's thyroiditis. // Clin Endocrinol — 1997 — Vol. 46. — P. 551 — 555.
  8. Tomer Y., Barbesino G., Greenberg D.A., Concepcion E., Davies T.F. Mapping the major susceptibility loci for familial Graves' and Hashimoto's diseases: Evidence for genetic heterogeneity and gene interactions. // J Clin Endocrinol Metab — 1999 — Vol. 84. — P. 4656 — 4664.
  9. Imrie H., Vaidya B., Perros P., et al. Evidence for a Graves' disease susceptibility locus at chromosome Xp11 in a United Kingdom population. // J Clin Endocrinol Metab — 2001 — Vol. 86. — P. 626 — 630.
  10. Chiovato L., Pinchera A. Stressful life events and Graves' disease. // Eur J Endocrinol. — 1996 — Vol. 134. — P. 680 — 682.
  11. Coles A., Wing M., Smith S., et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. // Lancet — 1999 — Vol. 354 — P. 1691-1695.
  12. Sato A., Takemura Y., Yamada T., et al. A possible role of immunoglobulin E in patients with hyperthyroid Graves' disease. // J Clin Endocrinol Metab — 1999 — Vol. 84. — P. 3602 — 3605.
  13. Rapoport B., Chazenbalk D., Jaume J.C., McLachlan S.M. The thyrotropin (TSH) receptor: Interaction with TSH and autoantibodies. // Endocrine Rev — 1998 — Vol. 19. — P. 673 — 716.
  14. Pichurin P., Pichurina O., Chazenbalk G.D., et al. Immune deviation away from Th1 in interferon-г knockout mice does not enhance TSH receptor antibody production after naked DNA vaccination. // Endocrinology — 2002 — Vol. 143. — P. 1182-1189.
  15. Chazenbalk G.D., McLachlan S.M., Pichurin P., Yan X-M., Rapoport B. A prion-like shift between two conformational forms of a recombinant thyrotropin receptor receptor A-subunit module: Purification and stabilization using chemical chaperones of the form reactive with Graves' autoantibodies. // J Clin Endocrinol Metab — 2001 — Vol. 86. — P. 1287 — 1293.
  16. Metcalfe R., Jordan N., Watson P., et al. Demonstration of immunoglobulin G, A, and E autoantibodies to the human thyrotropin receptor using flow cytometry. // J Clin Endocrinol Metab — 2002 — Vol. 87. — P. 1754-1761.
  17. McIntosh R.S., Tandon N., Pickerill A.P., Davies R., Barnett D., Weetman A.P. IL-2 receptor-positive intrathyroidal lymphocytes in Graves' disease. Analysis of Vб transcript microheterogeneity. // J Immunol — 1993 — Vol. 151. — P. 3884-3893.
  18. Soliman M., Kaplan E., Yanagawa T., Hidaka Y., Fisfalen M-E., DeGroot L.J. T cells recognize multiple epitopes in the human thyrotropin receptor extracellular domain. // J Clin Endocrinol Metab — 1995 — Vol. 80. — P. 905-914.
  19. Ajjan R.A., Kemp E.H., Waterman E.A., et al. Detection of binding and blocking autoantibodies to the human sodium-iodide symporter in patients with autoimmune thyroid disease. // J Clin Endocrinol Metab — 2000 — Vol. 85. — P. 2020-2027.
  20. Metcalfe R.A., McIntosh R.S., Marelli-Berg F., Lombardi G., Lechler R., Weetman A.P. Detection of CD40 on human thyroid follicular cells: Analysis of expression and function. // J Clin Endocrinol Metab — 1998 — Vol. 83. — P. 1268 — 1274.
  21. Schwartz K.M., Fatourechi V., Ahmed D.D.F., Pond G.R. Dermopathy of Graves' disease (pretibial myxedema): Long-term outcome. // J Clin Endocrinol Metab — 2002 — Vol. 87. — P. 438-446.
  22. Davies T.F., Roti E., Braverman L.E., DeGroot L.J. Controversy-Thyroid stimulating antibodies. // J Clin Endocrinol Metab — 1998 — Vol. 83. — P. 3777-3785.
  23. Costagliola S., Morgenthaler N.G., Hoermann R., et al. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. // J Clin Endocrinol Metab — 1999 — Vol. 84. — P. 90-97.
  24. Meller J., Jauho A., Hufner M., Gratz S., Becker W. Disseminated thyroid autonomy of Graves' disease: Reevaluation by a second generation TSH-receptor-antibody assay. // Thyroid — 2000 — Vol. 10. — P. 1085-1091.
  25. Feldt-Rasmussen U., Schleusener H., Carayon P. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on longterm remission after medical therapy of Graves' disease. // J Clin Endocrinol Metab — 1994 — Vol. 78. — P. 98-102.
  26. Ljunggren J-G., Torring O., Wallin G., et al. Quality of life aspects and costs in treatment of Graves' hyperthyroidism with antithyroid drugs, surgery, or radioiodine: Results from a prospective, randomized study. // Thyroid — 1998 — Vol. 8. — P. 653-659.
  27. Duh Q-Y. Thyroidectomy for the treatment of Graves' disease. // Thyroid — 1999 — Vol. 9. — P. 259-261.
  28. Singer P.A., Cooper D.S., Levy E.G., et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. // JAMA — 1995 — Vol. 273. — P. 808 — 812.
  29. Vanderpump M., Ahlquist J., Franklyn J.A., Clayton R.N. on behalf of a working group of the Research Unit of the Royal College of Physicians of London, the Endocrinology and Diabetes Committee of the Royal College of Physicians of London, and the Society for Endocrinology. Consensus statement for good practice and audit measures in the management of hypothyroidism and hyperthyroidism. // BMJ — 1996 — Vol. 313. — P. 539-544.
  30. Allahabadia A., Daykin J., Holder R.L., Sheppard M.C., Gough S., Franklyn J.A. Age and gender predict the outcome of treatment for Graves' hyperthyroidism. // J Clin Endocrinol Metab — 2000 — Vol. 85. — P. 1038-1042.
  31. Weetman A.P., Pickerill A.P., Watson P., Chatterjee V.K., Edwards O.M. Treatment of Graves' disease with the block-replace regimen of antithyroid drugs. The effect of treatment duration and immunogenetic susceptibility on relapse. // QJM — 1994 — Vol. 87. — P. 337 — 341.
  32. Maugendre D., Gatel A., Campion L., et al. Antithyroid drugs and Graves' disease — prospective randomised assessment of long-term treatment. // Clin Endocrinol — 1999 — Vol. 50. — P. 127-132.
  33. Hashizume K., Ichikawa K., Sakurai A., et al. Administration of thyroxine in treated Graves' disease: Effects on the level of antibodies to thyroid stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. // N Engl J Med — 1991 — Vol. 324. — P. 947-953.
  34. Rittmaster R.S., Abbot E.C., Douglas R., et al. Effect of methimazole, with or without L-thyroxine, on remission rates in Graves' disease. // J Clin Endocrinol Metab — 1998 — Vol. 83. — P. 814-818.
  35. McIver B., Rae P., Beckett G., Wilkinson E., Gold A., Toft A. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. // N Engl J Med — 1996 — Vol. 334. — P. 220-224.
  36. Tajiri J., Noguchi S., Murakami T., Murakami N. Antithyroid druginduced agranulocytosis. The usefulness of routine white blood cell count monitoring. // Arch Int Med — 1990 — Vol. 150. — P. 621-624.
  37. Williams K.V., Nayak S., Becker D., Reyes J., Burmeister L.A. Fifty years of experience with propylthiouracil-associated hepatotoxicity: What have we learned? // J Clin Endocrinol Metab — 1997 — Vol. 82. — P. 1727- 1733.
  38. Sera N., Ashizawa K., Ando T., et al. Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves' disease. // Thyroid — 2000 — Vol. 10. — P. 595-599.
  39. Jarlov A.E., Hegedus L., Kristensen L.O., Nygaard B., Hansen J.M. Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while? // Clin Endocrinol — 1991 — Vol. 43. — P. 325-329.
  40. Alexander E.K., Larsen P.R. High dose 131I therapy for the treatment of hyperthyroidism caused by Graves' disease. // J Clin Endocrinol Metab — 2002 — Vol. 87. — P. 1073-1077.
  41. Farrar J.J., Toft A.D. Iodine-131 treatment of hyperthyroidism: Current issues. // Clin Endocrinol — 1991 — Vol. 35. — P. 207-212.
  42. Kadmon P.M., Noto R.B., Boney C.M., Goodwin G., Gruppuso P.A. Thyroid storm in a child following radioactive iodine (RAI) therapy: A consequence of RAI versus withdrawal of antithyroid medication. // J Clin Endocrinol Metab — 2001 — Vol. 86. — P. 1865-1867.
  43. Imseis R.E., Vanmiddlesworth L., Massie J.D., Bush A.J., Vanmiddlesworth N.R. Pretreatment with propylthiouacil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism. // J Clin Endocrinol Metab. — 1998 — Vol. 83. — P. 685-687.
  44. Andrade V.A., Gross J.L., Maia L. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: One-year follow-up of a prospective, randomized study. // J Clin Endocrinol Metab. — 2001 — Vol. 86. — P. 3488-3493.
  45. Sabri O., Zimny M., Schulz G., et al. Success rate of radioiodine therapy in Graves' disease: The influence of thyrostatic medication. // J Clin Endocrinol Metab — 1999 — Vol. 84. — P. 1229-1233.
  46. Bartalena L., Marcocci C., Bogazzi F., et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. // N Engl J Med — 1998 — Vol. 338. — P. 73-78.
  47. Weetman A.P., Wiersinga W.M. Current management of thyroidassociated ophthalmopathy in Europe: Results of an international survey. // Clin Endocrinol — 1998 — Vol. 49. — P. 21-28.
  48. Ron E., Doody M.M., Becker D.V., et al. Cancer mortality following treatment for adult hyperthyroidism. // JAMA — 1998 — Vol. 280. — P. 347 — 355.
  49. Franklyn J.A., Maisonneuve P., Sheppard M.C., Betteridge J., Boyle P. Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: A population-based cohort study. // Lancet — 1999 — Vol. 353 — P. 2111 — 2115.
  50. Werga-Kjellman P., Zedenius J., Tallstedt L., Traisk F., Lundell G., Wallin G. Surgical treatment of hyperthyroidism: A ten-year experience. // Thyroid 2001 — Vol. 11. — P. 187-192.
  51. Mandel S.J., Cooper D.S. The use of antithyroid drugs in pregnancy and lactation. // J Clin Endocrinol Metab — 2001 — Vol. 86. — P. 2354 — 2359.
  52. Karlsson F.A., Axelsson O., Melhus H. Severe embryopathy and exposure to methimazole in early pregnancy. // J Clin Endocrinol Metab — 2002 — Vol. 87. — P. 947-948.
  53. Smith C., Thomsett M., Choong C., Rodda C., McIntyre H.D., Cotterill A.M. Congenital thyrotoxicosis in premature infants. // Clin Endocrinol — 2001 — Vol. 54. — P. 371-376.
  54. Laurberg P., Nygaard B., Glinoer D., Grussendort M., Orgiazzi J. Guidelines for TSH-receptor antibody measurements in pregnancy: Results of an evidence-based symposium organized by the European Thyroid Association. // Eur J Endocrinol — 1998 — Vol. 139. — P. 584-586.
  55. Azizi F., Khoshniat M., Bahrainian M., Hedayati M. Thyroid function and intellectual development of infants nursed by mothers taking methimazole. // J Clin Endocrinol Metab — 2000 — Vol. 85. — P. 3233 — 3238.
  56. Momotani N., Yamashita R., Makino F., et al. Thyroid function in wholly breast-feeding infants whose mothers take high doses of propylthiouracil. // Clin Endocrinol — 2000 — Vol. 53. — P. 177-181.
  57. Rivkees S.A., Sklar C., Freemark M. The management of Graves' disease in children, with special emphasis on radioiodine treatment. // J Clin Endocrinol Metab — 1998 — Vol. 83. — P. 3767-3776.
  58. Xiao H., Zhuang W., Wang S., et al. Arterial embolization: A novel approach to thyroid ablative therapy for Graves' disease. // J Clin Endocrinol Metab — 2002 — Vol. 87. — P. 3583 — 3589.

Для специалистов

Новостная рассылка

Поиск